Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network
Clark J, Garvey W, Niswender K, Schmidt A, Ahima R, Aleman J, Battarbee A, Beckman J, Bennett W, Brown N, Chandler‐Laney P, Cox N, Goldberg I, Habegger K, Harper L, Hasty A, Hidalgo B, Kim S, Locher J, Luther J, Maruthur N, Miller E, Sevick M, Wells Q. Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. Journal Of The American Heart Association 2023, 12: e027693. PMID: 36752232, PMCID: PMC10111504, DOI: 10.1161/jaha.122.027693.Peer-Reviewed Original ResearchConceptsAmerican Heart AssociationHeart AssociationWeight loss interventionNovel therapeutic approachesVanderbilt University Medical CenterUniversity Medical CenterEffective therapeutic interventionsField of obesityResearch NetworkLoss interventionClinical trialsWorldwide prevalenceMedical CenterTherapeutic approachesObesityTherapeutic targetAnimal modelsJohns Hopkins University SchoolTherapeutic interventionsIndividual centersNew targetsUniversity of AlabamaOverweightUniversity SchoolInterventionCancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association
Cohen J, Brown N, Brown S, Dent S, van Dorst D, Herrmann S, Lang N, Oudit G, Touyz R, Arteriosclerosis T. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2023, 80: e46-e57. PMID: 36621810, PMCID: PMC10602651, DOI: 10.1161/hyp.0000000000000224.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Heart AssociationAngiogenesis InhibitorsAntineoplastic AgentsHumansHypertensionMaleNeoplasmsVascular Endothelial Growth Factor AConceptsCardiovascular toxicityVascular endothelial growth factor inhibitorsCancer therapyEvidence-based clinical trialsNational hypertension guidelinesVascular endothelial growth factor receptorCardiovascular risk factorsDiscontinuation of treatmentCommon side effectsGrowth factor inhibitorsEndothelial growth factor receptorPrimary care professionalsAmerican Heart AssociationTyrosine kinase inhibitorsOptimal therapeutic effectNitric oxide generationGrowth factor receptorHypertension specialistsHypertension guidelinesSympathetic outflowAdjunctive therapyCardiovascular mortalityEndothelial dysfunctionHormone therapyBlood pressure